Biocon Licenses Seven In Asia To DKSH
Indian Firm’s Generics To Reach Singapore And Thailand
Keen to make strides for its growing Small Molecules business, Biocon has signed an agreement with DKSH to bring seven generic formulations to markets in South East Asia.
You may also be interested in...
Alvotech has partnered with DKSH to bring its high-concentration Humira rival to Asia. The Alvogen sister company plans to file the adalimumab biosimilar with the EMA and FDA in the second half of 2020.
Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.
Sandoz has failed to overturn on appeal an invalidity ruling for two patents covering Enbrel in the US, barring a path to market for its Erelzi biosimilar, potentially until patent expiry in 2029.